Which statement is true regarding the labeling requirements for blood products?

The requirement for a unique facility identifier, donor lot number, and ABO type on blood product labels is essential for ensuring the safety and traceability of blood transfusions. This comprehensive labeling serves multiple crucial purposes.

Firstly, the unique facility identifier allows for the tracking of the blood product back to the specific facility where it was collected and processed. This is critical in the event of a recall or investigation surrounding a blood-related issue.

Secondly, the donor lot number is significant for traceability, allowing healthcare providers to monitor and report any adverse reactions or complications related specifically to a batch of blood products. It aids in ensuring that all units of blood from a single donor can be identified and assessed similarly.

Thirdly, including the ABO type is vital to prevent transfusion reactions, which can occur if a patient receives blood that is not compatible with their blood type. Each of these components adds layers of safety and accountability to the handling and administration of blood products, which is why this statement about labeling requirements holds true.